In Brief: Isocam II safety update
This article was originally published in The Gray Sheet
Executive Summary
Isocam II safety update: Preliminary failure analysis by the U.K. Medical Devices Agency (MDA) and Park Medical Systems U.K. Ltd determines that the Isocam II dual-headed nuclear medicine gamma camera is "unsafe for clinical use and will require engineering modifications to render it safe." In light of this, FDA "recommends the immediate removal of the Isocam II from service until further notice," since the manufacturer, Park Medical Systems of Quebec, is no longer in business and Park U.K. does not do business in the U.S. FDA issued a safety alert on the Isocam II on Feb. 13 when MDA reported an incident where a "stainless steel plate from a harmonic drive motor failed, causing an arm of the system to fall into the gantry housing of the device" ("The Gray Sheet" Feb. 23, p. 22)...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.